Clear Labs Company Research Report

Company Overview

Company Name:

Clear Labs

Mission of the Company:

Clear Labs delivers access to genomics, data analytics, and actionable insights that protect life through innovative clinical and food safety next-generation sequencing and software solutions.

Founded:

• Year: 2014

• Founders: Sasan Amini and team

Key People:

• Sasan Amini: Co-Founder and CEO

• Ramin Khaksar: Co-Founder, CSO, and COO

• Edward Fan: Chief Financial Officer

• Henrik Gehrmann: Senior VP of Engineering

Headquartered:

• Location: 3565 Haven Ave #2, Menlo Park, CA 94025

Number of Employees:

• Employees: Over 50 teammates

Revenue:

• Revenue: No information is available

Known For:

Clear Labs is known for its fully automated, next-generation sequencing platforms for clinical diagnostics and food safety surveillance, including the Clear Dx™ and Clear Safety™ product lines.

Products

1. Clear Dx™

Clear Dx™ is a rapid, high-throughput next-generation sequencing (NGS) platform for clinical and public health labs. It offers complete characterization of microbial and viral pathogens, reducing hands-on time and turnaround time for results, enabling near real-time pathogen surveillance.

Key Features:

• Unrivaled Speed and Flexibility: Work faster with a fully automated sequencing platform.

• Consistent Results: Reduce workflow errors and generate the same outcome repeatedly.

• Streamlined Data Management: Manage and interpret data without the need for bioinformatics specialists.

• Accessibility and Ease of Use: Increase lab tech efficiency and productivity.

2. Clear Safety™

Clear Safety™ offers next-generation sequencing (NGS) food safety testing solutions for pathogens like Salmonella and Listeria. It ensures consumer safety by providing deep molecular characterization and ensuring operational efficiencies.

Key Features:

• The Power of Data: Improved decision-making based on insights achieved through NGS.

• Automated Workflow: Reduce labor and minimize errors with robotic pipetting and automated bioinformatics.

• Reliable Results: Reduce false negatives and positives, curtail recall risks, operational costs, holding time, and short-shipping penalties.

• Environmental Mapping: Visualize test results for better contamination incident management and corrective actions.

Recent Developments

New Products Launched:

• November 13, 2023: Clear Dx™ FlexPro: Wastewater (SARS-CoV-2), a fully automated end-to-end WGS solution for sequencing SARS-CoV-2 in wastewater.

• May 22, 2023: Clear Dx™ Microbial Surveillance WGS, a fully automated WGS solution for bacterial and fungal isolates.

New Features Added:

• February 18, 2024: New features for Clear Dx™ Microbial Surveillance WGS now accommodate additional sample input types including heat-inactivated bacterial isolates, extracted DNA, and cultured MTB.

Partnerships:

• December 2022: Clear Labs partnered with Illumina to include short-read sequencing-by-synthesis (SBS) technology in its fully integrated platform.

• March 2019: Distribution partnership with Oxford Nanopore Technologies to integrate long-read sequencing technology.

Notable Publications and Presentations:

• July 19, 2024: Publication on the next frontier in tuberculosis investigation using a fully automated WGS assay.

• July 1, 2024: Clear Labs' CSO and COO co-presented with Aviagen’s Laboratory Director at IAFP 2024.

• February 28, 2024: Publication on a targeted NGS assay for the direct detection and serotyping of Salmonella.

Major Achievements:

• May 2023: Launch of the Clear Dx™ Microbial Surveillance WGS expanding capabilities for pathogen outbreak detection.

• January 2021: Launch of a groundbreaking solution for surveillance of SARS-CoV-2 and its mutations.

• September 2020: Emergency Use Authorization (EUA) granted for Clear Dx™ SARS-CoV-2 diagnostic by the FDA.

• 2018 - 2019: Clear Safety™ Listeria and Salmonella received AOAC certification.

Clear Labs continues to expand its innovative solutions to accelerate outcomes, improve accuracy, and protect public health through advanced genomic and pathogen surveillance technologies.